Advertisement
Screener

Grace Therapeutics, Inc. (GRCE) Adjustments For Reconcile Profit Loss

2.8 / 5 stars · 68/120 Roast Me

Grace Therapeutics, Inc. Adjustments For Reconcile Profit Loss

Grace Therapeutics, Inc. (GRCE) reported Adjustments For Reconcile Profit Loss of -CAD 40.57 million for the 12-month period ending 2019-03-31, per its 20-F filed 2019-06-26.

Discontinued › Expense Statement › Operating Expenses

ifrs-full:AdjustmentsForReconcileProfitLoss · last filed 2019-06-26

Period endAdjustments For Reconcile Profit Loss 1 monthAdjustments For Reconcile Profit Loss 12 monthAdjustments For Reconcile Profit Loss 13 month
2019-03-31-40.57M CAD
20-F · filed 2019-06-26
2018-03-31-16.10M CAD
20-F · filed 2019-06-26
2017-03-31-418.00K CAD
20-F · filed 2019-06-26
-7.75M CAD
20-F · filed 2019-06-26
2017-02-28-7.33M CAD
20-F · filed 2019-06-26
2016-02-29-6.53M CAD
20-F · filed 2018-06-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
PDS Biotechnology Corp (PDSB)United States$0.045B
SCYNEXIS INC (SCYX)United States$0.045B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
VERU INC. (VERU)United States$0.043B-3.93
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98